Physician
American Oncology Partners PA
American Oncology Partners PA was paid $11.89M by Medicaid between Sep 2018 and Dec 2024, across 93 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 30% of everything it billed.
33Billing provider infoAMERICAN ONCOLOGY PARTNERS PA
COLUMBUS, OH 43219
COLUMBUS, OH 43219
33aNPI1265929723assigned 04/19/2018
33bProvider typeHematology (Internal Medicine) Physician
28Total paid$11.89M
24GClaims661,729
24DCodes billed93
24AFirst – last monthSep 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 5,938 | $62K | |
| 2019 | 46,631 | $303K | |
| 2020 | 103,560 | $1.31M | |
| 2021 | 114,753 | $1.78M | |
| 2022 | 126,911 | $2.40M | |
| 2023 | 145,968 | $3.68M | |
| 2024incomplete | 117,968 | $2.35M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 30% | 91,847 | 65,282 | $3.53M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 18% | 34,130 | 17,127 | $2.11M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 11% | 45,941 | 35,733 | $1.30M |
| J9271 | Injection, pembrolizumab, 1 mg | 8.4% | 170 | 127 | $997K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 6.0% | 168,785 | 107,087 | $711K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 3.0% | 5,305 | 3,795 | $358K |
| 99232 | Hospital visit by a doctor, follow-up daySubsequent hospital care, per day, moderate complexity | 2.3% | 6,625 | 1,907 | $268K |
| 96367 | 2.1% | 10,928 | 5,872 | $244K | |
| 36415 | Collection of venous blood by venipuncture | 1.9% | 138,816 | 90,227 | $231K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.9% | 6,290 | 3,476 | $224K |
| 99223 | Prolong inpt eval add15 m | 1.8% | 2,079 | 1,948 | $217K |
| J2469 | Injection, palonosetron hcl, 25 mcg | 1.1% | 5,820 | 3,244 | $136K |
81 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.0% | 12,933 | $124K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,679 | $119K |
| 80053 | Comprehensive metabolic panel | <1% | 34,861 | $117K |
| J0185 | Injection, aprepitant, 1 mg | <1% | 951 | $116K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,298 | $112K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 241 | $84K |
| J1437 | Injection, ferric derisomaltose, 10 mg | <1% | 148 | $84K |
| 96417 | <1% | 2,760 | $83K | |
| Q5126 | Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg | <1% | 47 | $70K |
| J0897 | Injection, denosumab, 1 mg | <1% | 80 | $67K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 991 | $66K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 2,433 | $63K |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | <1% | 38 | $53K |
| 82728 | <1% | 8,328 | $32K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 467 | $27K |
| 96523 | <1% | 1,573 | $22K | |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | <1% | 215 | $22K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,898 | $20K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 720 | $20K |
| 99205 | Prolong outpt/office vis | <1% | 175 | $17K |
| 96415 | <1% | 1,131 | $16K | |
| 82378 | <1% | 2,910 | $15K | |
| 82607 | <1% | 3,778 | $14K | |
| 84466 | <1% | 4,091 | $14K | |
| 96411 | <1% | 388 | $12K | |
| 83540 | <1% | 6,762 | $11K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 10,914 | $10K |
| 96416 | <1% | 131 | $10K | |
| 83735 | <1% | 4,683 | $9K | |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 219 | $9K |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 330 | $8K |
| 86300 | <1% | 2,019 | $8K | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 2,195 | $7K |
| 83550 | <1% | 3,639 | $7K | |
| 82784 | <1% | 973 | $7K | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 523 | $7K |
| 83615 | <1% | 3,643 | $6K | |
| 84165 | <1% | 2,142 | $6K | |
| 86334 | <1% | 1,318 | $5K | |
| 96368 | <1% | 503 | $5K | |
| 82746 | <1% | 1,534 | $5K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 599 | $5K |
| 99255 | <1% | 39 | $5K | |
| 83883 | <1% | 1,178 | $4K | |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | <1% | 87 | $4K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 133 | $4K |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 206 | $3K |
| J1750 | Injection, iron dextran, 50 mg | <1% | 66 | $3K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 50 | $3K |
| 99253 | <1% | 28 | $2K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 229 | $2K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 38 | $2K |
| 99221 | <1% | 29 | $1K | |
| 88185 | <1% | 17 | $1K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 33 | $1K |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 228 | $1K |
| 86304 | <1% | 129 | $1K | |
| 99254 | <1% | 15 | $1K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 30 | $1K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,776 | $967.28 |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 32 | $827.86 |
| 51798 | <1% | 334 | $668.65 | |
| 99442 | <1% | 49 | $582.20 | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 42 | $535.11 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 487 | $516.79 |
| 86301 | <1% | 58 | $510.28 | |
| 81002 | <1% | 824 | $433.81 | |
| 84153 | <1% | 128 | $402.09 | |
| 84439 | <1% | 100 | $339.51 | |
| G0452 | Molecular pathology procedure; physician interpretation and report | <1% | 45 | $297.34 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 74 | $180.62 |
| 84100 | <1% | 145 | $169.50 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 42 | $164.84 |
| 88184 | <1% | 17 | $96.44 | |
| 83010 | <1% | 16 | $79.68 | |
| 88189 | <1% | 18 | $71.01 | |
| J3490 | Unclassified drugs | <1% | 127 | $63.36 |
| 82962 | <1% | 38 | $21.85 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 16 | $19.33 |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation agreement | 0% | 1,723 | $0.00 |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 0% | 106 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialOLSON, RYAN (OWNER/PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| American Oncology Partners of Hawaii, LLC | Honolulu, HI | $46K |
| Chetek Ambulance Service | Chetek, WI | $19K |
| American Oncology Partners, P.A. | Lebanon, IN | $153.76 |
| American Oncology Partners, P.A. | Zachary, LA | $62.65 |
| American Oncology Partners, P.A. | Indianapolis, IN | $25.89 |
| American Oncology Partners, P.A. | Indianapolis, IN | $7.20 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.